Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

ADC Advances and Updated PARP Indications Support Focus on Individualized Approaches in Ovarian Cancer

September 6th 2023

Heather R. Williams, MD, expands on updated data from the the phase 3 PRIMA trial initially supporting the use of frontline PARP inhibitor maintenance in ovarian cancer, as well as changing indications for niraparib based on data from the NOVA trial.

Generic Drug Shortage of Platinum Agents in Ovarian Cancer Sends Cautionary Signal

September 6th 2023

The well-publicized severe shortage of vitally important generic antineoplastic agents has highlighted a serious misalignment in the existing market-based and regulatory environment that permitted such an extraordinary situation to develop without meaningful resolution.

Maintenance Mirvetuximab Soravtansine Plus Bevacizumab Under Exploration in FRα+ Ovarian Cancer

September 1st 2023

The efficacy of maintenance mirvetuximab soravtansine plus bevacizumab is being compared with bevacizumab alone in patients with folate receptor alpha–positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancers that did not progress on second-line triplet therapy in the phase 3 GLORIOSA study.

Dendritic Cell Vaccines Represent Potential Avenue to Enhance Immunotherapy in Ovarian Cancer

September 1st 2023

Martin Cannon, PhD, delves into ongoing research on the use of dendritic cell vaccines to generate Th17 responses in patients with ovarian cancer and details how this could address a need for select patients with ovarian cancer.

Cracking the Immunotherapy Code Remains a Challenge in Ovarian Cancer

August 31st 2023

Martin Cannon, PhD, details the history of investigating immune checkpoint inhibitors in patients with ovarian cancer and expands on the questions that need to be answered to potentially improve the activity of these agents in this patient population.

Dr Williams on the Evolution of Treatment Approaches in Ovarian Cancer

August 30th 2023

Heather R. Williams, MD, discusses the evolution of the ovarian cancer treatment paradigm over the past several decades, as well as the importance of continuing to investigate individualized treatment approaches in this population to expand therapeutic options after disease recurrence.

Dr Cannon on Improving Responses With Immunotherapy in Ovarian Cancer

August 30th 2023

Martin Cannon, PhD, discusses explanations for the lack of success with immune checkpoint inhibitors in ovarian cancer, and how to potentially improve responses to immunotherapy approaches in this tumor type.

TTFields Plus Paclitaxel Misses OS End Point in Platinum-Resistant Ovarian Cancer

August 28th 2023

The addition of tumor treating fields to paclitaxel did not result in a statistically significant improvement in overall survival vs paclitaxel alone in patients with platinum-resistant ovarian cancer, failing to meet the primary end point of the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial.

Niraparib Maintenance Extends PFS in Newly Diagnosed Ovarian Cancer

August 27th 2023

Maintenance therapy with the PARP inhibitor niraparib prolonged progression-free survival vs placebo in patients with newly diagnosed advanced ovarian cancer.

Dr Williams on the Mechanism of Action of ADCs in Ovarian Cancer

August 25th 2023

Heather R. Williams, MD, discusses the mechanism of action of antibody-drug conjugates and ADC targets under investigation in patients with ovarian cancer.

Dr Williams on Eye Toxicities Associated With ADCs in Ovarian Cancer

August 24th 2023

Heather R. Williams, MD, discusses ocular toxicities associated with antibody-drug conjugates and strategies for managing these toxicities in patients with ovarian cancer.

Dr Cannon on the Investigation of the Th17 Dendritic Cell Vaccine in Ovarian Cancer

August 23rd 2023

Martin Cannon, PhD, discusses the phase 1 investigation of the Th17 dendritic cell vaccine in ovarian cancer, and how it could potentially improve suboptimal responses when treated with immunotherapy alone in this population.

Dr Birrer on the Potential Utility of ADCs in Platinum-Resistant Ovarian Cancer

August 22nd 2023

Michael J. Birrer, MD, PhD, discusses how the expansion of antibody-drug conjugates can address the need for more effective regimens in platinum-resistant ovarian cancer.

Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 Study

August 22nd 2023

Whitney S. Graybill, MD, MS, presents data from an analysis of the phase 3 PRIMA trial that looked to identify baseline characteristics associated with long-term progression-free survival with niraparib in patients with advanced ovarian cancer.

Dr Moore on the Phase 1/2 Study Investigating Ubamatamab in Ovarian Cancer

August 21st 2023

Kathleen N. Moore, MD, MS, discusses the eligibility criteria for the ongoing, first-in-human, phase 1/2 study of ubamatamab, a MUC16- and CD3-targeted bispecific antibody, alone or in combination with cemiplimab in patients with recurrent ovarian cancer.

Dr Williams on the Importance of Investigating ADCs in Ovarian Cancer

August 16th 2023

Heather R. Williams, MD, discusses the importance of further exploring the use of antibody drug conjugates in ovarian cancer, specifically highlighting the investigation of mirvetuximab soravtansine in this population.

Ofranergene Obadenovec Plus Paclitaxel Misses the Mark in Platinum-Resistant Ovarian Cancer

August 11th 2023

The addition of ofranergene obadenovec to paclitaxel failed to significantly improve survival outcomes compared with paclitaxel alone in patients with platinum-resistant ovarian cancer.

Dr Barroilhet on the Role of PARP Inhibitors in BRCA+ and HRD Ovarian Cancer

August 10th 2023

Lisa Barroilhet, MD, discusses the role of PARP inhibitors in patients with ovarian cancer.

Future Outlook for Treatment of Endometrial Cancer

August 10th 2023

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

Ongoing Trials in Endometrial Cancer

August 10th 2023

An overview of ongoing research in the endometrial cancer treatment space.